Satisfy Online Ad Requirements with NABP’s Healthcare Merchant Accreditation
If you are involved in the business of health care, it’s likely that you could benefit from obtaining our Healthcare Merchant Accreditation. As our broadest and most accessible accreditation program, Healthcare Merchant Accreditation is offered to both brick-and-mortar businesses and online-only enterprises around the world, enabling your business to meet requirements to advertise on platforms […]
Read More ›Embracing Innovative Technologies for the Future of Pharmacy
In the years since the pandemic, recent NABP Presidents Reginald B. “Reggie” Dilliard, DPh, and Lenora S. Newsome, PD, focused their energies on addressing changes and challenges we face as pharmacists and as regulators. This important work included adapting and continuing pharmacy workplace changes that were put in place during the pandemic and working towards […]
Read More ›Licensure Transfer Updates Provide Solutions for Pharmacists
Pharmacist Licensure Transfer Yesterday and Today For over a century, NABP has served a key role in licensure transfer for pharmacists from one jurisdiction to another. Before NABP’s assistance, licensure transfer could be a challenging maze of hurdles for boards of pharmacy and pharmacists represented by different requirements, processes, and delays. Over the years, our […]
Read More ›Understanding the Current Ketamine Landscape
What is Ketamine? Finding information online about ketamine can be overwhelming, leaving a lot of patients and their families confused about its approved uses. Simply put, ketamine is an anesthetic with some hallucinogenic properties and is classified as a Schedule III non-narcotic substance under the federal Controlled Substances Act. It can only be prescribed by […]
Read More ›Working to Support Pharmacist Mental Health and Well-Being
Since NABP President Lenora S. Newsome, PD, assumed office, we have been hard at work assisting her with her presidential initiative to support mental health and well-being for pharmacy staff. Since the COVID-19 pandemic, pharmacy staff has been under immense stress that has reached a critical point, leading to rampant burnout and resignation. NABP staff […]
Read More ›New Look, Same Great Features on CPE Monitor
Recently, CPE Monitor, NABP’s continuing pharmacy education (CPE) tracking tool, was updated to provide a more modern interface that offers a better, more streamlined experience. And if you subscribe to the Plus plan, navigating your requirements for license renewal and staying compliant—whether you have 1 license or 15—is now even easier with the improved platform. […]
Read More ›Diabetes Drug Shortages and Fake Ozempic
Injectable diabetes medications including semaglutide, namely Wegovy and Ozempic, have been in shortage since 2022, limiting patient access to the drug across the nation. Many other drugs have appeared on FDA’s shortage list in the past few years, including ADHD medications, chemotherapy treatments, and even antibiotics. However, the semaglutide shortage has been featured prominently in […]
Read More ›Xylazine and Opioid Overdoses Spur Government Action
Since the beginning of the COVID-19 pandemic, a disruption in access to opioid use disorder (OUD) treatment and recovery services, as well as increased social isolation and stress, contributed to a new surge of overdose deaths. The emergence of illicit falsified prescriptions containing synthetic opioids, notably fentanyl, has contributed to this crisis. Amid these continued […]
Read More ›NABP’s Verified Pharmacy Program Celebrates 10th Anniversary
This year, NABP’s Verified Pharmacy Program® (VPP®) is celebrating its 10th anniversary. Since its inception in 2013, VPP has become the most widely recognized multistate uniform pharmacy inspection program accepted by state boards of pharmacy. To date, VPP has completed over 2,400 on-site inspections. The program provides access to verified pharmacy licensure details, VPP inspection […]
Read More ›What Trading Partners Need to Know Before the DSCSA Deadline
Full implementation of the Drug Supply Chain Security Act (DSCSA) was to begin on November 27, 2023. However, on August 25, 2023, US Food & Drug Administration (FDA) issued what it refers to as a “Stabilization Policy,” — a one-year period of non-enforcement for certain DSCSA requirements. In our view, FDA expects drug supply chain […]
Read More ›